- Opinion
- [Desk View] Can NHI alone cover the costs of cancer drugs?
- by Lee, Tak-Sun Aug 20, 2025 06:23am
- The reimbursement claim amount submitted for anti-cancer drugs has been increasing robustly every year. According to the '2024 Pharmaceutical Reimbursement Claims Data' published by the Health Insurance Review & Assessment Service, drug expenditure for cancer diseases in 2024 amounted to KRW 4.1372 trillion, a 7.4% increase from KRW 3.850
- Opinion
- [Reporter's View] Innovation exists in treating all diseases
- by Eo, Yun-Ho Aug 20, 2025 06:23am
- When discussing Korea’s insurance reimbursement system, the qualifier “life-threatening” has long been a source of frustration. It is no exaggeration to say that, for the pharmaceutical industry, this phrase has been the number one target for removal since the very beginning. This was the case in determining eligibility for the Risk Sh
- Company
- Expanded patent dispute over cancer drug 'Xtandi'
- by Kim, Jin-Gu Aug 20, 2025 06:22am
- The number of companies challenging the patent for Astellas' prostate cancer treatment, 'Xtandi (enzalutamide)', has expanded to six. Attention has been drawn to the fact that major pharmaceutical companies, such as Chong Kun Dang, Hanmi Pharmaceutical, and JW Pharmaceutical, have joined this latest patent challenge. According to the phar
- Policy
- MFDS's bill on stable supply of essential drugs in review
- by Lee, Jeong-Hwan Aug 20, 2025 06:22am
- A bill to add “medicines that are essential for healthcare and require stable supply” and “medicines with similar therapeutic effects with no alternative treatments” to the list of national essential medicines, thereby resolving the issue of unstable supply of medicines, is likely to pass the Health and Welfare Committee's legislative su
- InterView
- Dong-A ST launches Sterlara biosimilar Imuldosa in the US
- by Cha, Jihyun Aug 20, 2025 06:22am
- Dong-A ST (CEO: Jae-Hoon Jeong) announced on the 19th that the company has launched IMULDOSA (project name DMB-3115, active ingredient ustekinumab), a biosimilar version of Stelara, in the US through its partners, multinational pharmaceutical companies Intas Pharmaceuticals and Accord Biopharma. IMULDOSA is biosimilar version of Janssen’
- Company
- Dapa N with Forxiga's indication leads the mkt by surprise
- by Kim, Jin-Gu Aug 20, 2025 06:22am
- Prescription sales of HK inno.N's 'Dapa N,' which received transfer of Forxiga indications, have surged in the SGLT-2 inhibitor diabetes treatment market. It has risen to the top of the dapagliflozin monotherapy market. Analysis suggests that this success is attributed to Dapa N's transition in indications, including chronic heart failu
- Company
- Reimb for 'Padcev' combo as a 1st-line treatment reapplied
- by Whang, byung-woo Aug 19, 2025 06:12am
- Will 'Padcev+Keytruda' combination therapy overcome the reimbursement hurdle in the area of metastatic urothelial cancer, where the first-line treatment option had not been available? In terms of treatment effectiveness, there is no disagreement among experts that, in the long term, it is a first-line standard treatment option. With Astellas
- Policy
- MOHW proposes an alternative to law on generic substitution
- by Lee, Jeong-Hwan Aug 19, 2025 06:11am
- A revision to the Pharmaceutical Affairs Act that would allow pharmacies to report generic substitution to the Health Insurance Review and Assessment Service (HIRA) through its work portal is likely to pass the National Assembly. The background to the sudden increase in the likelihood of legislation is that the Ministry of Health and Welf
- Opinion
- [Reporter's View] Clarify support for unstable supply drugs
- by Lee, Hye-Kyung Aug 19, 2025 06:11am
- The Ministry of Food and Drug Safety is reportedly preparing support measures to stabilize the supply of national essential medicines and other items with unstable supply. The MFDS initially announced its intention to specify the urgent measures required by the industry to stabilize supply, such as emergency imports, custom manufacturing, an
- Company
- Will Wegovy patients switch to Mounjaro? Doctors skeptical
- by Moon, sung-ho Aug 19, 2025 06:11am
- With the anticipated launch of Lilly Korea's diabetes and obesity treatment Mounjaro (tirzepatide) in mid-August, its full-scale competition with Novo Nordisk's Wegovy (semaglutide) is expected to unfold. Amid the imminent competition, the issue of whether to switch between the two drugs has emerged as a key point of contention in clinical se
